Hillsdale Investment Management Inc. Raises Stock Position in Bioventus Inc. $BVS

Hillsdale Investment Management Inc. raised its stake in shares of Bioventus Inc. (NASDAQ:BVS) by 148.7% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 671,139 shares of the company’s stock after purchasing an additional 401,230 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Bioventus were worth $6,128,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in BVS. Caitong International Asset Management Co. Ltd boosted its stake in shares of Bioventus by 17,156.2% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock valued at $41,000 after purchasing an additional 5,490 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of Bioventus during the fourth quarter valued at about $80,000. Diversified Trust Co bought a new position in Bioventus in the first quarter worth about $100,000. Prelude Capital Management LLC bought a new position in Bioventus in the third quarter worth about $74,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Bioventus in the third quarter worth about $78,000. 62.94% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BVS has been the topic of several research reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $15.00 price objective on shares of Bioventus in a research report on Tuesday, June 16th. CJS Securities began coverage on Bioventus in a research report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 target price for the company. Weiss Ratings restated a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd. Finally, Barrington Research restated an “outperform” rating and set a $14.00 price target on shares of Bioventus in a research report on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Bioventus presently has an average rating of “Buy” and an average price target of $14.75.

Bioventus Price Performance

BVS stock opened at $11.56 on Wednesday. The firm has a 50 day moving average price of $9.80 and a 200-day moving average price of $9.05. Bioventus Inc. has a 52-week low of $5.81 and a 52-week high of $12.30. The firm has a market capitalization of $965.66 million, a price-to-earnings ratio of 28.20, a PEG ratio of 1.54 and a beta of 0.65. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.06. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.The company had revenue of $132.09 million for the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Equities research analysts forecast that Bioventus Inc. will post 0.79 EPS for the current fiscal year.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.